Corrêa Gustavo C, Uddin Md Jasim, Wahed Tasnuva, Oliveras Elizabeth, Morgan Christopher, Kamya Moses R, Kabatangare Patience, Namugaya Faith, Leab Dorothy, Adjakidje Didier, Nguku Patrick, Attahiru Adam, Sequeira Jenny, Vollmer Nancy, Reynolds Heidi W
Gavi, The Vaccine Alliance, Chemin du Pommier 40, Le Grand Saconnex, 1218 Geneva, Switzerland.
International Centre for Diarrhoeal Disease Research, Bangladesh, 68 Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka 1212, Bangladesh.
Vaccines (Basel). 2024 Feb 14;12(2):195. doi: 10.3390/vaccines12020195.
Zero-dose (ZD) children is a critical objective in global health, and it is at the heart of the Immunization Agenda 2030 (IA2030) strategy. Coverage for the first dose of diphtheria-tetanus-pertussis (DTP1)-containing vaccine is the global operational indicator used to estimate ZD children. When surveys are used, DTP1 coverage estimates usually rely on information reported from caregivers of children aged 12-23 months. It is important to have a global definition of ZD children, but learning and operational needs at a country level may require different ZD measurement approaches. This article summarizes a recent workshop discussion on ZD measurement for targeted surveys at local levels related to flexibilities in age cohorts of inclusion from the ZD learning Hub (ZDLH) initiative-a learning initiative involving 5 consortia of 14 different organizations across 4 countries-Bangladesh, Mali, Nigeria, and Uganda-and a global learning partner. Those considerations may include the need to generate insights on immunization timeliness and on catch-up activities, made particularly relevant in the post-pandemic context; the need to compare results across different age cohort years to better identify systematically missed communities and validate programmatic priorities, and also generate insights on changes under dynamic contexts such as the introduction of a new ZD intervention or for recovering from the impact of health system shocks. Some practical considerations such as the potential need for a larger sample size when including comparisons across multiple cohort years but a potential reduction in the need for household visits to find eligible children, an increase in recall bias when older age groups are included and a reduction in recall bias for the first year of life, and a potential reduction in sample size needs and time needed to detect impact when the first year of life is included. Finally, the inclusion of the first year of life cohort in the survey may be particularly relevant and improve the utility of evidence for decision-making and enable its use in rapid learning cycles, as insights will be generated for the population being currently targeted by the program. For some of those reasons, the ZDLH initiative decided to align on a recommendation to include the age cohort from 18 weeks to 23 months, with enough power to enable disaggregation of key results across the two different cohort years. We argue that flexibilities with the age cohort for inclusion in targeted surveys at the local level may be an important principle to be considered. More research is needed to better understand in which contexts improvements in timeliness of DTP1 in the first year of life will translate to improvements in ZD results in the age cohort of 12-23 months as defined by the global DTP1 indicator.
零剂次(ZD)儿童是全球卫生领域的一个关键目标,也是《2030年免疫议程》(IA2030)战略的核心。含白喉-破伤风-百日咳(DTP1)疫苗首剂接种覆盖率是用于估算ZD儿童的全球业务指标。在进行调查时,DTP1覆盖率估算通常依赖于12至23个月龄儿童看护人报告的信息。对ZD儿童有一个全球定义很重要,但国家层面的学习和业务需求可能需要不同的ZD测量方法。本文总结了最近一次研讨会的讨论内容,该研讨会围绕ZD学习中心(ZDLH)倡议针对地方层面目标调查的ZD测量展开,该倡议是一项学习倡议,涉及孟加拉国、马里、尼日利亚和乌干达4个国家的14个不同组织组成的5个联盟以及一个全球学习伙伴。这些考虑因素可能包括需要深入了解免疫及时性和补种活动情况,在疫情后背景下这一点尤为重要;需要比较不同年龄队列年份的结果,以便更好地系统识别遗漏社区并验证项目重点,还要深入了解动态背景下的变化情况,例如引入新的ZD干预措施或从卫生系统冲击的影响中恢复过来;一些实际考虑因素,比如纳入多个队列年份进行比较时可能需要更大样本量,但寻找符合条件儿童的家访需求可能会减少,纳入年龄较大组时回忆偏差会增加,而一岁以内回忆偏差会减少,纳入一岁以内队列时检测影响所需的样本量需求和时间可能会减少。最后,在调查中纳入一岁以内队列可能特别重要,可提高决策证据的效用,并使其能用于快速学习周期,因为将为该项目当前的目标人群生成见解。出于其中一些原因,ZDLH倡议决定采纳一项建议,纳入18周龄至23个月龄的年龄队列,具备足够的效力以便按两个不同队列年份对关键结果进行分类。我们认为,在地方层面目标调查中纳入年龄队列的灵活性可能是一个需要考虑的重要原则。需要开展更多研究,以更好地了解在哪些情况下一岁以内DTP1接种及时性的改善会转化为全球DTP1指标所定义的12至23个月龄年龄队列中ZD结果的改善。